Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2009
11/19/2009US20090286864 Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith
11/19/2009US20090286863 Sulfamatobenzothiophene derivatives
11/19/2009US20090286862 Therapeutic agent for psychoneurotic disease
11/19/2009US20090286861 Phenotypic reversion of pancreatic carcinoma cells
11/19/2009US20090286860 Method of using adenoviral vectors to induce an immune response
11/19/2009US20090286859 POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1a EXPRESSION
11/19/2009US20090286858 Assays for modulators of asparaginyl hydroxylase
11/19/2009US20090286857 Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
11/19/2009US20090286856 Method of Diagnosing Breast Cancer
11/19/2009US20090286855 Interleukin-18 mutants, their production and use
11/19/2009US20090286854 Aptamers directed to muci
11/19/2009US20090286853 Modified oligonucleotides for telomerase inhibition
11/19/2009US20090286852 RNA containing modified nucleosides and methods of use thereof
11/19/2009US20090286851 Compositions and Methods for Delivering RNAI Using Lipoproteins
11/19/2009US20090286850 Inhibition of EMT induction in tumor cells by anti-cancer agents
11/19/2009US20090286849 Modulation of insulin like growth factor i receptor expression
11/19/2009US20090286848 Novel n-(2-amino-phenyl)-acrylamides
11/19/2009US20090286847 Oncogenic ras-specific cytotoxic compound and methods of use thereof
11/19/2009US20090286846 such as N-(1-Methyl-1H-indol-5-yl)-1-(3-trifluoromethylbenzyl)-1H-indole-2-carboxamide, for the treatment of of bladder hyperactivity, hyperreflexia or instability, incontinence, urgent urination, urinary incontinence, cystitis, renal colic, pelvic hypersensitivity, pelvic pain, asthma and cough
11/19/2009US20090286845 Carvedilol phosphate
11/19/2009US20090286844 Carvedilol phosphate
11/19/2009US20090286843 Macrocyclic compounds as inhibitors of viral replication
11/19/2009US20090286842 Naphthylmethylimidizoles as therapeutic agents
11/19/2009US20090286841 Certain chemical entities, compositions, and methods
11/19/2009US20090286840 Polo-like kinase inhibitors such as 5-(5-Amino-2H-pyrazol-3-yl)-3-[1-(2-chloro-phenyl)-ethoxy]-thiophene-2-carboxylic acid amide, useful for treating or preventing autoimmune, inflammatory, proliferative or hyperproliferative disease, a neurodegenerative disease, or an immunologically-mediated disease
11/19/2009US20090286839 Phytonutrient compositions from mushrooms or filamentous fungi and methods of use
11/19/2009US20090286838 Treatment for cancer
11/19/2009US20090286837 Oxadiazole compounds as urokinase inhibitors
11/19/2009US20090286836 Novel Compounds
11/19/2009US20090286835 Novel compounds
11/19/2009US20090286834 Pyridine Analogues VI
11/19/2009US20090286833 Substituted Cyclohexylmethyl Compounds
11/19/2009US20090286832 Narcotic emulsion formulations for treatment of surgical pain
11/19/2009US20090286831 VR1 Receptor Ligands and u-Opioid Receptor Ligands for the Treatment of Pain
11/19/2009US20090286830 administering drugs such as 6-[1-[1-[(2-aminopyridin-4-yl)methyl]-4-fluoropiperidine-4-carbonyl]piperidin-4-yl]oxypyridine-3-carbonitrile, for the treatment of cognition deficit disorder in a patient suffering from Alzheimer's disease or schizophrenia
11/19/2009US20090286829 Quinolynylmethylimidizoles as therapeutic agents
11/19/2009US20090286828 2-amino-1-phenylethylcarboxamide derivatives
11/19/2009US20090286827 Novel bi-aryl amines
11/19/2009US20090286826 Pharmaceutical compositions having carboxyvinyl polymer and povidone polymer
11/19/2009US20090286825 {7-[[(4-fluorophenyl)sulfonyl](methyl)amino]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl}acetic acid; prostaglandine D2 receptor antagonists ; respiratory, inflammatory or allergic conditions; chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2)
11/19/2009US20090286824 Pyridine Classical Cannabinoid Compounds and Related Methods of Use
11/19/2009US20090286823 CCR1 Inhibitors useful for the treatment of multiple myeloma and other disorders
11/19/2009US20090286822 Treatment of psoriasis and of other skin disorders associated with inhibition of differentiation of epidermal cells
11/19/2009US20090286821 Inhibitors of tyrosine kinases
11/19/2009US20090286820 (r)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their use
11/19/2009US20090286819 Process for Preparing the Calcium Salt of Rosuvastatin
11/19/2009US20090286818 Pyridine Non-Classical Cannabinoid Compounds and Related Methods of Use
11/19/2009US20090286817 Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester
11/19/2009US20090286816 Modulators of metabolism and the treatment of disorders related thereto
11/19/2009US20090286815 Pyrimidine Classical Cannabinoid Compounds and Related Methods of Use
11/19/2009US20090286814 Hcv protease inhibitors
11/19/2009US20090286813 Thioxanthine Derivatives and Their Use as Inhibitors of MPO
11/19/2009US20090286812 GPR119 Receptor Agonists
11/19/2009US20090286811 Fused pyrimidineone compounds as trpv3 modulators
11/19/2009US20090286810 Pyrimidine Non-Classical Cannabinoid Compounds and Related Methods of Use
11/19/2009US20090286809 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound
11/19/2009US20090286808 Opsin Stabilizing Compounds and Methods of Use
11/19/2009US20090286807 Cyclic amine compound
11/19/2009US20090286806 Isoxazole derivatives as calcium channel blockers
11/19/2009US20090286805 Solubiliazation preparation
11/19/2009US20090286804 Metabolites of 1-[6-(1-ethyl-1-hydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]-pyrrolidin-2-one as seratonin receptor antagonists
11/19/2009US20090286803 Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
11/19/2009US20090286802 High Dose Folic Acid Compositions for Vascular Dysfunction
11/19/2009US20090286801 Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands
11/19/2009US20090286800 Glucokinase Activators
11/19/2009US20090286799 Methods for the treatment of brain edema
11/19/2009US20090286798 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
11/19/2009US20090286797 Novel Quinoxaline Derivatives and Their Medical Use
11/19/2009US20090286796 Compounds exhibiting type X sPLA2 inhibiting effect
11/19/2009US20090286795 Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
11/19/2009US20090286794 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound
11/19/2009US20090286793 Pde4b inhibitors and uses therefor
11/19/2009US20090286792 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
11/19/2009US20090286791 Amide Compounds
11/19/2009US20090286790 Organic compounds
11/19/2009US20090286789 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases
11/19/2009US20090286787 Substituted gamma lactams as therapeutic agents
11/19/2009US20090286786 Compounds having a 4-pyridylalkylthio group as a substituent
11/19/2009US20090286785 Pyrimidine Derivatives
11/19/2009US20090286784 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
11/19/2009US20090286783 Pyrrolo(2,3-d)pyrimidine kinase inhibitors; melanoma, colorectal cancer, pain, polycystic kidney disease and other Raf protein kinase related conditions; e.g. Propane-1-sulfonic acid[3-(4-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluoro-phenyl]-amide; Raf kinases including B-raf, A-raf
11/19/2009US20090286782 Compounds and methods for kinase modulation, and indications therefor
11/19/2009US20090286781 Use of Suluble Guanylate Cyclase Acitvators for Treating Acute and Chronic Lung Diseases
11/19/2009US20090286780 2-oxochromene derivatives
11/19/2009US20090286779 Pyrazolopyrimidines as lipid kinase inhibitors
11/19/2009US20090286778 Macrocyclic compounds and their use as kinase inhibitors
11/19/2009US20090286777 5,6,Fused Pyrrolidine Compounds Useful as Tachykinin Receptor Antagonists
11/19/2009US20090286776 Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
11/19/2009US20090286775 Bicyclic Derivatives as P38 Kinase Inhibitors
11/19/2009US20090286774 Purinone derivatives as hm74a agonists
11/19/2009US20090286773 Kinase inhibitors
11/19/2009US20090286772 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles
11/19/2009US20090286771 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders
11/19/2009US20090286770 Use of Staurosporine Derivatives for the Treatment of Multiple Myeloma
11/19/2009US20090286769 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
11/19/2009US20090286768 Substituted imidazopyr- and imidazotri-azines
11/19/2009US20090286767 Substituted quinolin-4-ylamine analogues
11/19/2009US20090286766 Azolecarboxamide derivative
11/19/2009US20090286765 Therapeutic Agents
11/19/2009US20090286764 Stable pharmaceutical formulations
1 ... 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2511 2512 2513 2514 ... 7860